FY2021 Q3
Financial Briefing Material
February 7, 2022
JMDC Inc.
Section 1
Performance Report for FY2021 Q3
2
FY2021 Q3: Performance Highlights
All business segments, particularly Healthcare-Big Data, expanded steadily. The organic growth of our core business is driving the overall growth.
Consolidated revenue
(Million JPY)
15,679
Y-o-Y
+35％
Consolidated EBITDA
(Million JPY)
4,580
Y-o-Y
+39％
Healthcare-
Big Data
Y-o-Y
+46％
Tele-medicine and
Dispensing
Pharmacy Support
Y-o-Y | |
Tele-medicine | Dispensing |
Pharmacy Support |
+12％ +32％
JMDC
(non-consolidated)
net sales growth
Y-o-Y
+39％
JMDC
(non-consolidated)
EBITDA growth
Y-o-Y
+63％
3
Note: IFRS-based
EBITDA: Operating profit + Depreciation and amortization costs ± Other profits and/or losses
FY2021 Q3: Summary of Consolidated Performance
We maintain a high level of profitability by expanding our workforce in balance with our business growth.
(Unit: Million JPY)
FY2020 Q3 | FY2021 Q3 | Y-o-Y |
Revenue
Operating profit
(Rate)
Profit before taxes
(Rate)
Profit attributable to
owners of parent
(Rate)
EBITDA (Margin)
11,606 | 15,679 |
2,424 | 3,417 |
(21%) | (22%) |
2,406 | 3,408 |
(21%) | (22%) |
1,578 | 2,280 |
(14%) | (15%) |
3,284 | 4,580 |
(28%) | (29%) |
+35%
+41%
+42%
+44%
+39%
4
Note: IFRS-based
EBITDA: Operating profit + Depreciation and amortization costs ± Other profits and/or losses, EBITDA margin: EBITDA/Revenue
FY2021 Q3: Consolidated Revenue/EBITDA
The trend of the previous fiscal quarter, when performance expanded rapidly, has been firmly sustained.
Quarterly trends of consolidated revenue | Quarterly trends of consolidated EBITDA/margin | |
(Unit: Million JPY) | (Unit: Million JPY and %) |
+ 32% | ||||||||||
6,128 | ||||||||||
4,630 | 5,165 | 4,530 | 5,020 | |||||||
3,503 | 3,212 | 3,763 | ||||||||
3,068 | 3,028 | |||||||||
2,558 | ||||||||||
Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 |
FY2019 | FY2020 | FY2021 |
35 | 34 | |||||||||
EBITDA | 31 | |||||||||
margin | ||||||||||
+ 30% | ||||||||||
2,107 | ||||||||||
EBITDA | 1,619 | 1,582 | ||||||||
1,164 | 1,308 | |||||||||
934 | 993 | 1,050 | ||||||||
835 | ||||||||||
614 | ||||||||||
480 | ||||||||||
Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 |
FY2019 | FY2020 | FY2021 |
5
Note: IFRS-based
EBITDA: Operating profit + Depreciation and amortization costs ± Other profits and/or losses, EBITDA margin: EBITDA/Revenue
This is an excerpt of the original content. To continue reading it, access the original document here.